3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
28
HER2-positive Breast Cancer
4
Neoplasms
3
Multiple Myeloma
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Brain Neoplasms
2
Anatomic Stage II Breast Cancer AJCC v8
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Salivary Gland Neoplasms
1
Resectable HER2-positive Breast Cancer
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Melanoma
1
Malignant Solid Neoplasm
1
Lymphoma
1
Interventions
fludarabine
2
durvalumab
2
Cyclophosphamide
2
ruxolitinib
1
repotrectinib
1
ponatinib
1
pembrolizumab
1
gilteritinib
1
fludarabine phosphate
1
cemiplimab
1
atezolizumab
1
Whole-Body Irradiation
1
Tacrolimus
1
Peripheral Blood Stem Cell Transplantation
1
Pemetrexed
1
Patient Reported Outcome Measures
1
Nivolumab
1
Mycophenolic Acid
1
Mesna
1
Melphalan
1
Immunotherapy
1
Idarubicin
1
Granulocyte Colony-Stimulating Factor
1
Docetaxel
1
Cytarabine
1
Cisplatin
1
CPI-0610
1
Busulfan
1
Bone Marrow Transplantation
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
pertuzumab
×
90 days
×
Clear all
No trials found.